Table 2.
Onset of exposure and glucose-lowering effect after administration of faster aspart versus insulin aspart (0.2 U/kg) in elderly subjects with type 1 diabetes mellitus
| Faster asparta | Insulin asparta | Treatment ratiob [95% CI] | Treatment differencec [95% CI] | p valued | |
|---|---|---|---|---|---|
| Onset of exposure | |||||
| Onset of appearance (min) | 2.4 | 5.2 | 0.45 [0.30–0.60] | –2.9 [–3.8 to −1.9] | <0.001 |
| t Early 50% Cmax (min) | 18.2 | 28.0 | 0.65 [0.56–0.74] | –9.8 [–12.7 to −7.0] | <0.001 |
| t max (min) | 57.2 | 64.2 | 0.89 [0.75–1.06] | –7.0 [–17.6 to 3.6] | 0.187 |
| Onset of glucose-lowering effect | |||||
| Onset of action (min) | 19.0 | 29.1 | 0.65 [0.51–0.81] | –10.2 [–15.3 to −5.1] | <0.001 |
| t Early 50% GIRmax (min) | 32.1 | 37.7 | 0.85 [0.77–0.94] | –5.6 [–9.0 to −2.2] | 0.003 |
| tGIRmax (min) | 136.2 | 145.8 | 0.93 [0.79–1.10] | –9.6 [–33.7 to 14.5] | 0.415 |
CI confidence interval, t Early 50% Cmax time to 50% of maximum insulin aspart concentration in the early part of the pharmacokinetic profile, t Early 50% GIRmax time to 50% of maximum glucose infusion rate in the early part of the glucose infusion rate profile, tGIR max time to maximum glucose infusion rate, t max time to maximum insulin aspart concentration
aData are least square means
bFaster aspart/insulin aspart (calculated using Fieller’s method)
cFaster aspart – insulin aspart
dFor treatment comparison of faster aspart versus insulin aspart